Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

David S Alberts, P. Y. Liu, S. P. Wilczynski, A. Jang, J. Moon, J. H. Ward, J. T. Beck, M. Clouser, M. Markman

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with stage III or IV ovarian cancer, whose tumor expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and with relapse of measurable disease within 6 months of completing frontline, platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg of imatinib mesylate orally. It was assumed that the agent would be of no further interest if the population response rate was less than 10%. A two-stage design was used for patient accrual. A total of 34 patients were registered to the study. Of these, 15 were found to be ineligible or not evaluable (8 because their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable patients, 2 (11%) tested positively for c-Kit and 17 (89%) tested positively for PDGFR. There were no objective responders. Thirteen patients (68%) had increasing disease or symptomatic deterioration, and six (32%) went off protocol during the first month due to adverse events. Median progression-free survival was 2 months (95% CI 1-3 months) and median overall survival was 10 months (95% CI 6-18 months). Eleven percent of patients experienced grade 4 hematologic/metabolic toxicity and 37% experienced grade 3 nonhematologic toxicity. We conclude that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)784-788
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume17
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

Ovarian Neoplasms
Biomarkers
Platelet-Derived Growth Factor Receptors
Platinum
Imatinib Mesylate
Population
Disease-Free Survival
Neoplasms
Recurrence
Drug Therapy
Survival

Keywords

  • Imatinib mesylate
  • Kit (CD117)
  • Ovarian cancer
  • PDGFR

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). / Alberts, David S; Liu, P. Y.; Wilczynski, S. P.; Jang, A.; Moon, J.; Ward, J. H.; Beck, J. T.; Clouser, M.; Markman, M.

In: International Journal of Gynecological Cancer, Vol. 17, No. 4, 07.2007, p. 784-788.

Research output: Contribution to journalArticle

Alberts, David S ; Liu, P. Y. ; Wilczynski, S. P. ; Jang, A. ; Moon, J. ; Ward, J. H. ; Beck, J. T. ; Clouser, M. ; Markman, M. / Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). In: International Journal of Gynecological Cancer. 2007 ; Vol. 17, No. 4. pp. 784-788.
@article{eadee60bf4b842499f40d8ca2a60ee73,
title = "Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)",
abstract = "Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with stage III or IV ovarian cancer, whose tumor expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and with relapse of measurable disease within 6 months of completing frontline, platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg of imatinib mesylate orally. It was assumed that the agent would be of no further interest if the population response rate was less than 10{\%}. A two-stage design was used for patient accrual. A total of 34 patients were registered to the study. Of these, 15 were found to be ineligible or not evaluable (8 because their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable patients, 2 (11{\%}) tested positively for c-Kit and 17 (89{\%}) tested positively for PDGFR. There were no objective responders. Thirteen patients (68{\%}) had increasing disease or symptomatic deterioration, and six (32{\%}) went off protocol during the first month due to adverse events. Median progression-free survival was 2 months (95{\%} CI 1-3 months) and median overall survival was 10 months (95{\%} CI 6-18 months). Eleven percent of patients experienced grade 4 hematologic/metabolic toxicity and 37{\%} experienced grade 3 nonhematologic toxicity. We conclude that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer.",
keywords = "Imatinib mesylate, Kit (CD117), Ovarian cancer, PDGFR",
author = "Alberts, {David S} and Liu, {P. Y.} and Wilczynski, {S. P.} and A. Jang and J. Moon and Ward, {J. H.} and Beck, {J. T.} and M. Clouser and M. Markman",
year = "2007",
month = "7",
doi = "10.1111/j.1525-1438.2007.00882.x",
language = "English (US)",
volume = "17",
pages = "784--788",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

AU - Alberts, David S

AU - Liu, P. Y.

AU - Wilczynski, S. P.

AU - Jang, A.

AU - Moon, J.

AU - Ward, J. H.

AU - Beck, J. T.

AU - Clouser, M.

AU - Markman, M.

PY - 2007/7

Y1 - 2007/7

N2 - Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with stage III or IV ovarian cancer, whose tumor expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and with relapse of measurable disease within 6 months of completing frontline, platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg of imatinib mesylate orally. It was assumed that the agent would be of no further interest if the population response rate was less than 10%. A two-stage design was used for patient accrual. A total of 34 patients were registered to the study. Of these, 15 were found to be ineligible or not evaluable (8 because their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable patients, 2 (11%) tested positively for c-Kit and 17 (89%) tested positively for PDGFR. There were no objective responders. Thirteen patients (68%) had increasing disease or symptomatic deterioration, and six (32%) went off protocol during the first month due to adverse events. Median progression-free survival was 2 months (95% CI 1-3 months) and median overall survival was 10 months (95% CI 6-18 months). Eleven percent of patients experienced grade 4 hematologic/metabolic toxicity and 37% experienced grade 3 nonhematologic toxicity. We conclude that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer.

AB - Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with stage III or IV ovarian cancer, whose tumor expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and with relapse of measurable disease within 6 months of completing frontline, platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg of imatinib mesylate orally. It was assumed that the agent would be of no further interest if the population response rate was less than 10%. A two-stage design was used for patient accrual. A total of 34 patients were registered to the study. Of these, 15 were found to be ineligible or not evaluable (8 because their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable patients, 2 (11%) tested positively for c-Kit and 17 (89%) tested positively for PDGFR. There were no objective responders. Thirteen patients (68%) had increasing disease or symptomatic deterioration, and six (32%) went off protocol during the first month due to adverse events. Median progression-free survival was 2 months (95% CI 1-3 months) and median overall survival was 10 months (95% CI 6-18 months). Eleven percent of patients experienced grade 4 hematologic/metabolic toxicity and 37% experienced grade 3 nonhematologic toxicity. We conclude that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer.

KW - Imatinib mesylate

KW - Kit (CD117)

KW - Ovarian cancer

KW - PDGFR

UR - http://www.scopus.com/inward/record.url?scp=34447318659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447318659&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.00882.x

DO - 10.1111/j.1525-1438.2007.00882.x

M3 - Article

C2 - 17343607

AN - SCOPUS:34447318659

VL - 17

SP - 784

EP - 788

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -